Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Impedance Testing

By Drug Discovery Trends Editor | July 22, 2010

Bionas GmbH announces the launch of its new Bionas adcon reader for impedance-based, cellular analysis. The Bionas adcon reader technology is based on real-time monitoring of cellular impedance, thus giving real-time data about cell adhesion, membrane integrity, cellular morphology and cell proliferation for applications in toxicology, oncology, receptor signaling as well as the quality management of cells.  Bionas technology allows for the analysis of cellular behavior in real-time without the use of any dyes or antibodies, thus avoiding the result being biased by the manipulation of the cells during the assay. The Bionas adcon reader consists of the Bionas plate station, the Bionas analyzer and a control unit (PC) and offers easy handling in 96-well format for laboratory research and HTS applications.

Also this summer, Bionas will launch the Bionas 15002 RtU-Transporter system, an advancement of the existing two-channel Bionas 15002 analyzing system, but especially adapted for the analysis of membrane transport mechanisms and their role in multidrug resistances. It is the first automatic, label-free test system in the area of membrane transporter research, measuring impedance, O2-consumption and acidification.

With the new analyzing systems, Bionas is responding to the increasing demand of the life science community for label-free, real-time assays.  Bionas is convinced that the recognized Bionas 2500 analyzing system, for real-time monitoring of impedance (adhesion), acidification and O2-consumption, will be perfectly complemented by the new Bionas adcon reader and the Bionas 15002 RtU-Transporter system. The Bionas 2500 analyzing system so far, is the only analyzing system that generates real-time data of three parameters in parallel.

Bionas GmbH


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50